Granted Patent
B2
US 7,875,424 · App. 10/573,229 · Granted Jan 25, 2011
Identification of tumour-associated cell surface antigens for diagnosis and therapy
Assignee:
Ganymed Pharmaceuticals, AG
View Patent ↗
Loading inventors, assignments & file history…
Abstract
According to the invention, tumour-associated gene products and nucleic acids coding therefor were identified. The present invention relates to the therapy and diagnosis of diseases wherein said tumour-associated gene products are expressed aberrantly. The invention also relates to proteins, polypeptides and peptides which are expressed in a tumour-associated manner and the nucleic acids coding therefor.
Claims (1)
1. A method for diagnosing melanoma in a patient, the method comprising detecting the presence of a nucleic acid comprising the nucleic acid of SEQ ID NO: 1 in a skin sample from the patient.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 1, 2019
From: GANYMED PHARMACEUTICALS GMBH
To: BIONTECH SE
Reel/Frame 049641/0269 →
CHANGE OF NAME
Recorded May 16, 2019
From: GANYMED PHARMACEUTICALS, AG
To: GANYMED PHARMACEUTICALS GMBH
Reel/Frame 049613/0217 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 8, 2007
From: TURECI, OZLEM; SAHN, UGUR; HELFTENBEIN, GERD; SCHLUTER, VOLKER
To: GANYMED PHARMACEUTICALS AG
Reel/Frame 019426/0755 →
Priority Claims (1)
DE 103 44 799
· Sep 26, 2003
· national
Continuity (1)